



129 Morgan Drive
Norwood, MA 02062

voice: (781) 551-9450
fax: (781) 440-9528
email: apogee@apogeebio.com

FOR IMMEDIATE RELEASE

Apogee Investor Contact:

Paul J. Murphy
Chief Financial Officer and Vice President of Finance
Telephone: (781) 551-9450

Apogee Technology Announces the Publication of an Article on Intradermal Immunization in the Proceedings of the National Academy of Sciences of the U.S.A. (PNAS)

NORWOOD, Mass. (October 26, 2009) — Apogee Technology (ATCS.PK), a life sciences company focused on the development of vaccine and drug delivery systems, today announced publication of an article on its intradermal immunization approach in the Online Early Edition of PNAS (the Proceedings of the National Academy of Sciences of the USA). An article entitled “Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization” describes important findings on the *in vivo* and *in vitro* performance of Company’s microneedle technology and demonstrates effective intradermal vaccination from an adjuvanted patch delivery system. The technology, when used as part of an intradermal delivery system for hepatitis B surface antigen, demonstrated superior activity in the appropriate animal model compared to conventional intramuscular administration. It also provided significant dose sparing potential – the property, which can be highly desirable during times of vaccine shortages, such as epidemic emergencies, and for reducing the cost of vaccine manufacturing. The manuscript, scheduled to be published this week, is coauthored by researchers from Apogee’s R&D team and collaborators from three Universities in United States and Canada.

“We are honored to have this research published in the PNAS as it serves as an important validation of Apogee’s approach to intradermal vaccination,” says Alexander K. Andrianov, Ph.D., Apogee’s Vice President of Research & Development and corresponding co-author of the paper. “Intradermal immunization using microneedles has not been fully compatible with many vaccine adjuvants including alum, the most common adjuvant used in the vaccine market globally. We believe that introduction of polyphosphazene immunoadjuvant of the present study as a biologically potent and synergistic constituent of microneedle-based intradermal vaccine delivery represents an important step forward in the advancement of our technology.”

About Apogee Technology, Inc.

Apogee Technology, Inc. is a biotechnology company developing proprietary systems for the delivery of pharmaceutical agents into the skin for the treatment and prevention of local and systemic conditions. The Company’s PyraDerm™ delivery system incorporates structured solid-state formulations designed to penetrate the outer layer of the skin and then release the agent in a controlled manner. For more information please visit our web site at: <http://www.apogeebio.com>.

##

PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders.



129 Morgan Drive
Norwood, MA 02062

voice: (781) 551-9450
fax: (781) 440-9528
email: apogee@apogeebio.com

Certain statements made herein that use the words "anticipate," "may," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve those related to the use of proceeds from the private placement, the design, development and production efforts of our PyraDerm™ and Sensilica® technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the Company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its report on Form 10-KSB, as amended, for the year ended December 31, 2007, as updated in its quarterly reports on Form 10-Q. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.